BeiGene, a global oncology company, has announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Rosenberg will succeed Julia Wang, who is leaving to pursue other opportunities but will remain with the company through August to ensure a smooth transition.
John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene, expressed enthusiasm about Rosenberg’s arrival during a pivotal year for the company. “We are excited to welcome Aaron at a time when BeiGene has emerged as a top 15 global oncology innovator by revenue. With a strong focus on reaching profitability and a robust pipeline that includes plans for at least 10 new molecular entities this year, Aaron’s financial expertise and proven success at Merck & Co. will be critical as we expand our business and reinforce our leadership in hematology while building new strengths in other prevalent cancers, such as lung, breast, and gastrointestinal,” Oyler said. He also acknowledged Wang’s significant contributions, including scaling financial operations to support the company’s growth from 4,000 to over 10,000 employees, driving the successful global launch of BRUKINSA®, and raising substantial capital.
Rosenberg, a seasoned finance executive with over 20 years at Merck & Co., Inc., was most recently Senior Vice President and Corporate Treasurer. “I’m honored to join BeiGene at such a transformative moment. I am deeply committed to BeiGene’s mission of advancing cancer treatments globally and look forward to contributing to the company’s continued success,” Rosenberg said.
Before his role as Corporate Treasurer, Rosenberg served as Senior Vice President of Corporate Strategy and Planning at Merck and led the enterprise-wide business transformation team. He also held the position of Vice President and Finance Lead for Merck Animal Health. Rosenberg began his career at Merck in 2003, advancing through various leadership roles in global finance.
Rosenberg holds a Bachelor of Science in Finance from the Warrington College of Business at the University of Florida and an MBA from the Leonard N. Stern School of Business at New York University.
About BeiGene
BeiGene is dedicated to discovering and developing innovative, accessible cancer treatments. With a comprehensive portfolio and a growing global team of over 10,000 employees across five continents, the company is accelerating the development of its novel therapeutics through internal efforts and collaborations. For more information, visit www.beigene.com and follow BeiGene on LinkedIn, X (formerly Twitter), Facebook, and Instagram.
Forward-Looking Statements
This press release includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements about BeiGene’s expected new molecular entities, progress towards profitability, and future business plans. Actual results may differ significantly due to various factors, including the efficacy and safety of drug candidates, regulatory actions, commercial success, intellectual property protection, reliance on third parties, and the need for additional funding. For more details, see BeiGene’s most recent quarterly report on Form 10-Q and subsequent SEC filings. The company undertakes no obligation to update this information unless required by law.
